National Heart, Lung, and Blood Institute (NHLBI)
The National Heart, Lung, and Blood Institute is one of the 27 institutes and centers that make up the National Institutes of Health, operating under the U.S. Department of Health and Human Services. This page covers NHLBI's statutory mandate, its funding and research mechanisms, the disease categories it addresses, and how its priorities differ from those of adjacent NIH components. Understanding NHLBI's scope is essential for researchers, clinicians, and public health professionals navigating federal biomedical funding and evidence-based cardiovascular and pulmonary medicine.
Definition and scope
NHLBI holds the federal mandate to conduct and support research, training, and education on the causes, prevention, diagnosis, and treatment of heart, lung, and blood diseases, as well as sleep disorders. Established under the Public Health Service Act, the institute traces its legislative authority through statutes codified at 42 U.S.C. § 285b, which directs the Secretary of Health and Human Services to maintain a national program targeting cardiovascular, pulmonary, and hematologic conditions (ecfr.gov).
The scope of diseases covered is broad but precisely bounded. Cardiovascular conditions include coronary artery disease, heart failure, arrhythmias, and congenital heart defects. Pulmonary conditions encompass asthma, chronic obstructive pulmonary disease (COPD), pulmonary hypertension, and acute respiratory distress syndrome. Blood and hematologic diseases include sickle cell disease, hemophilia, aplastic anemia, and disorders of coagulation. Sleep disorders—particularly sleep apnea and its cardiovascular consequences—fall within NHLBI's portfolio as a result of legislative additions that recognized the intersection of sleep physiology with cardiac and pulmonary function.
NHLBI's annual budget places it among the largest NIH institutes. In fiscal year 2023, NHLBI received an appropriation of approximately $4.1 billion (NIH Office of Budget), funding extramural grants, intramural laboratory programs, and large-scale population studies. For a broader view of how federal appropriations flow across all NIH institutes, the NIH home reference provides orientation to the agency's overall structure and funding mechanisms.
How it works
NHLBI operates through two parallel research tracks—extramural and intramural—that serve distinct functions within the broader NIH research ecosystem. A fuller treatment of those structural distinctions appears on the NIH intramural vs. extramural research page.
Extramural program: The majority of NHLBI funding—historically above 80 percent of its budget—flows outward to universities, medical schools, research hospitals, and independent investigators through competitive grants (NIH Office of Budget). Grant mechanisms include:
- R01 Research Project Grants — the standard investigator-initiated mechanism for hypothesis-driven research with multi-year budgets, typically up to 5 years per award cycle.
- U01 Cooperative Agreements — used for large multi-site clinical trials where NHLBI program staff maintain substantial involvement in study design and execution.
- P01 Program Project Grants — support integrated, multi-component research programs addressing a shared scientific theme.
- N01 Contract Mechanisms — procurement contracts for specific research deliverables, commonly used for NHLBI's large epidemiological cohort studies.
- K-series Career Development Awards — structured mentored research training for early-career investigators transitioning toward independence.
Intramural program: NHLBI's intramural division conducts laboratory and clinical research at the NIH campus in Bethesda, Maryland. Investigators hold federal appointments and are not subject to the competitive grant renewal cycle, allowing pursuit of longer-horizon scientific questions. The intramural program has produced foundational work in cardiac physiology, hematology, and pulmonary biology.
NHLBI also administers population-level observational cohorts that generate the epidemiological evidence base for cardiovascular risk factor science. The Framingham Heart Study, operated in collaboration with Boston University under NHLBI sponsorship, has followed three generations of participants since 1948 and remains one of the longest-running cardiovascular cohort studies in biomedical history (NHLBI Framingham Heart Study).
Common scenarios
NHLBI funding and resources appear across a predictable set of institutional and investigator situations:
Academic medical centers pursuing cardiovascular trials: A cardiology department at a research university seeking to conduct a Phase III randomized controlled trial on a heart failure intervention would typically apply for a U01 cooperative agreement. NHLBI program officers collaborate on protocol development, and the institute may co-fund a coordinating center separate from the investigative sites.
Early-career physician-scientists: A cardiologist completing fellowship training who wishes to transition to independent research applies for a K08 Mentored Clinical Scientist Research Career Development Award or a K23 award for patient-oriented research. These mechanisms provide salary support—generally covering 75 percent of effort—while the investigator develops a research program under a senior mentor's supervision.
Sickle cell disease research: NHLBI serves as the primary federal home for sickle cell disease research given the condition's classification as a blood disorder. Investigators studying gene therapy, disease-modifying pharmacological agents, or health disparities in sickle cell outcomes compete for NHLBI funding specifically, rather than through the National Cancer Institute or the National Institute of Allergy and Infectious Diseases—distinctions that matter when identifying the correct funding institute during application.
Population health and prevention programs: NHLBI funds the National Cholesterol Education Program and similar public health translation initiatives that move research findings into clinical guidelines and community-level interventions.
Decision boundaries
Understanding where NHLBI's mandate ends and another institute's begins prevents misdirected applications and clarifies the federal research architecture.
NHLBI vs. National Cancer Institute (NCI): When a research project addresses lung cancer specifically, NCI (National Cancer Institute overview) holds primary jurisdiction even though the lung is an NHLBI organ system. NHLBI's pulmonary portfolio covers non-malignant lung disease. A study on lung cancer immunotherapy belongs with NCI; a study on post-cancer-treatment pulmonary fibrosis may involve both institutes in co-funding arrangements.
NHLBI vs. National Institute of Allergy and Infectious Diseases (NIAID): Asthma research with an immunological or allergic mechanism focus often overlaps with NIAID's mandate. NIAID (NIAID overview) addresses immune-mediated mechanisms broadly, while NHLBI addresses the pulmonary and airway physiology dimensions. Investigators submit to the institute whose scientific emphasis most closely matches the project's primary aims, with dual-assignment reviews possible.
NHLBI vs. National Institute on Aging (NIA): Cardiovascular aging and age-related decline in pulmonary function represent a shared boundary. NIA (National Institute on Aging) focuses on the biology and epidemiology of aging as a process; NHLBI focuses on organ-specific disease regardless of patient age. A study on arterial stiffness in older adults could appropriately target either institute depending on whether the mechanistic focus is aging biology or cardiovascular pathophysiology.
Clinical trials vs. observational studies: Within NHLBI, interventional clinical trials require compliance with additional oversight structures, including registration in ClinicalTrials.gov (NIH clinical trials overview) and adherence to NIH's human subjects research protections framework (NIH human subjects research protections). Observational cohort studies carry distinct IRB and data-sharing obligations under NHLBI's data access policies.
NHLBI's peer review follows the standard NIH Center for Scientific Review process for most R01 and K-series applications, with institute-specific study sections convened for specialized topics in cardiovascular and pulmonary biology (NIH peer review process).